By the end of the 6-month TB treatment period, Ki67 and CD95 expression had decreased, whereas Bcl-2 and CD127 expression increased in CFP-10/ESAT-6-specific CD8 T cells, compared with pre-treatment levels (Figure 4C). Here, BCL2 is linked to tuberculosis.